753-P: Eating Behavior in Adults with Type 2 Diabetes from a Phase 2 Study of Retatrutide

Retatrutide (RETA), a triple-hormone receptor agonist of GIP, GLP-1, and glucagon receptors, showed clinically meaningful improvements in HbA1c and robust body weight reductions in adults with T2D in a Phase 2 study. We compared eating behavior during treatment with RETA vs. placebo or dulaglutide (DU) in this study. Adults with T2D were randomized to subcutaneous placebo QW, DU 1.5 mg QW, or RETA 0.5, 4, 8, or 12 mg QW for 36 weeks in this double-blind, double-dummy Phase 2 study. Eating behavior was assessed at baseline and Week 36 using the 51-item Eating Inventory comprised of three domains: Cognitive Restraint of Eating, Disinhibition, and Perceived Hunger. Overall, 281 adults with mean baseline age 56 y, T2D duration 8.1 y, HbA1c 8.3%, and BMI 35.0 kg/m2 were randomized. At Week 36, adults treated with RETA 8 mg and 12 mg had significantly reduced Eating Inventory Disinhibition and Perceived Hunger scores vs. placebo. Adults treated with RETA 12 mg also had significantly reduced Disinhibition and Perceived Hunger scores vs. DU and a significantly reduced Cognitive Restraint of Eating score vs. placebo at Week 36. RETA treatment significantly improved some eating behaviors such as overeating and hunger management more than placebo or DU in a dose-dependent manner, and improved other eating behaviors such as portion control and avoiding high calorie foods more than placebo in adults with T2D. Disclosure C. Kanu: None. K. Boye: Employee; Eli Lilly and Company. J. Poon: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. I.A. Goetz: Employee; Eli Lilly and Company. S.E. Williamson: Consultant; Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novo Nordisk, Lundbeck. J. Lou: None. T. Coskun: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Funding Eli Lilly and Company